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Pandemic (H1N1) 2009 inﬂuenza is affecting countries in all ﬁve continents, with most cases so far having been
reported in North and South America and Europe, and children and young adults being the most susceptible
age groups. To date, the clinical course of disease is typically mild, with low hospitalization and mortality
rates. Pandemic (H1N1) 2009 is susceptible to oseltamivir and, although few clinical data are yet available,
current information suggests that treatment with oseltamivir appears to be beneﬁcial. Only isolated cases of
resistance to the drug have been reported to date, in keeping with the low frequency observed in clinical
studies involving patients infected with seasonal inﬂuenza viruses. Current health authority guidelines rec-
ommend the use of oseltamivir in infected adults and children who have or are at elevated risk for severe
disease, including pregnant women; use during the pandemic in infants ,1 year has also been authorized in
Europe and a number of other countries, including the USA and Canada. Before the onset of the current pan-
demic, F. Hoffmann-La Roche Ltd expanded annual production capacity for oseltamivir to 400 million treat-
ment courses per year to meet anticipated demand. However, during an inﬂuenza pandemic, and despite
increased production capabilities, resources are nonetheless likely to be initially in short supply. For this
reason, Roche, in line with WHO recommendations, has advocated advance stockpiling of antivirals by govern-
ments as a pandemic preparedness measure. Between 2004 and December 2009, 350 million treatment
courses were supplied to governments worldwide. Support for developing countries has been a priority.
Roche has established a cluster of initiatives aimed at increasing access to Tamiﬂu for the world’s developing
economies, including, making donations to the WHO, establishing the Tamiﬂu Reserves Program (TRP) and sub-
licensing and manufacturing contracts with local companies in Asia and Africa. Furthermore, Roche has pub-
lished a document outlining how it would allocate limited supplies of Tamiﬂu during a pandemic, which are
in line with WHO recommendations stating that ‘resources should be used to provide the maximum possible
health beneﬁt’. Roche is also offering support such as reprocessing of expiring capsule stocks (in development)
and shelf-life extension to support governments in the management of their stockpiles. Clinical studies, either
sponsored by or supported by Roche, are in progress. These trials are designed to investigate the effectiveness
of oseltamivir in patients infected with the pandemic virus in greater depth, and include high-dose studies,
assessment of natural and drug-induced resistance, and response to treatment in high-risk populations such
as young infants, immunocompromised patients and the severely ill.
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Epidemiology and prevalence of pandemic
inﬂuenza A (H1N1) 2009
As had been widely predicted by medical and public health
experts, the current inﬂuenza pandemic reached Phase 6 on 11
June 2009, indicated by sustained community level outbreaks
in more than one WHO region. Pandemic inﬂuenza A (H1N1)
2009 is a triple-reassortant virus containing genes from inﬂuenza
viruses of avian, human and swine origin,
1 and the ﬁrst human
infections caused by this virus were reported in Mexico in April
2009. By 22 November 2009, laboratory-conﬁrmed cases of
infection had been reported in 207 countries across ﬁve
continents, affecting a total of .622482 people, the great
majority of which (84%) were reported to three WHO Regional
Ofﬁces, namely the Americas (190765 cases), Europe
(.154000) and the Western Paciﬁc (176796).
2 These incidence
ﬁgures underestimate the actual number of cases, because
countries where community-wide transmission has occurred
are no longer required to identify all individual cases.
3 Indeed,
by mid-July 2009, .1 million people were estimated to have
been infected in the USA.
4
Children and young adults seem to be more susceptible to the
disease than older people,
5–7 although transmission to older
adults may occur later in the epidemic. The incubation period for
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ii35pandemic inﬂuenza A (H1N1) 2009 is not yet certain, but appears
to range from 2 to 7 days.
1 In most cases, clinical signs are mild
and similar to those seen with seasonal inﬂuenza infections,
typically including fever, cough and sore throat (Figure 1).
5–7
So far, the numbers of patients hospitalized have been small
and, given the large number of mild unreported cases, the
hospitalization rate is probably ,1%.
4 Primary viral pneumonia
is the most common complication, with bacterial pneumonia
being less frequent.
4 Severe disease appears to be most
common in children ,5 years old, pregnant women and those
with underlying medical conditions such as lung or heart disease,
or immunosuppression.
8,9 Danger signs that signal progression to
more severe disease include shortness of breath, difﬁculty
breathing, turning blue, chest pain, altered mental status, persist-
ent high fever and low blood pressure.
9 The current mortality rate
for pandemic (H1N1) 2009 is low—as of 22 November 2009,
7826 of the .622482 cases (1.3%) reported to the WHO had a
fatal outcome.
2
Activity of oseltamivir against pandemic
inﬂuenza A (H1N1) 2009
Oseltamivir (Tamiﬂu
w; F. Hoffmann-La Roche Ltd) is currently
approved for use in adults and children aged  1 year of age,
and has also recently been approved in Europe for children
,1 year of age infected with pandemic inﬂuenza.
10 Emergency
authorization has recently been granted in the USA, Canada
and several other countries for use in infants ,1 year old with
pandemic (H1N1) 2009.
11,12 In addition to patients with severe
disease caused by the pandemic virus, guidance from the
WHO, the CDC and the European Centre for Disease Prevention
and Control (ECDC)
11,13,14 recommends that pregnant women
should be added to the other recognized groups of high-risk
patients (children aged ,5 years, the over-65s, immunosup-
pressed patients and those with concomitant diseases) for
whom oseltamivir treatment should be used. Early treatment
initiation within 48 h of symptoms is also recommended,
although initiation after 48 h is considered beneﬁcial.
11,13,14
The WHO and the CDC have conﬁrmed that the pandemic
(H1N1) 2009 virus is susceptible to oseltamivir,
2,11 with suscepti-
bility being very similar to that of drug-susceptible seasonal
viruses (Table 1).
1
Although information on clinical effectiveness of oseltamivir
in pandemic (H1N1) 2009 is currently limited, early reports
from Japan and Vietnam suggest that treatment may be ben-
eﬁcial. All except 1 of 49 mostly adolescent patients hospitalized
in Kobe City, Japan with pandemic (H1N1) 2009 received either
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Figure 1. Frequency of symptoms at presentation in conﬁrmed cases of pandemic (H1N1) 2009 infection in the UK as of 31 May 2009 (n¼175).
Reproduced from HPA, Health Protection Scotland, National Public Health Service for Wales, HPA Northern Ireland Swine inﬂuenza investigation
teams
7 with permission.
Table 1. Susceptibility of 37 isolates of swine-origin inﬂuenza A (H1N1)
virus to neuraminidase inhibitors compared with control values from
seasonal inﬂuenza viruses; adapted from Novel S-OIV Investigation
Team 2009
1
Oseltamivir IC50
(nmol/L)
Zanamivir IC50
(nmol/L)
mean median mean median
All 37 isolates 0.57 0.54 0.59 0.59
Reference seasonal viruses
oseltamivir susceptible 0.63 — 0.60 —
oseltamivir resistant 265.27 — 1.27 —
IC50, concentration producing inhibition in 50% of the sample.
Reddy
ii36oseltamivir (22) or zanamivir (26).
15 Both medications were
well tolerated, and earlier administration seemed to be
associated with a reduced duration of fever [median duration
of fever of 1.5 days (range 1–4 days) with oseltamivir and
1 day (range 1–5 days) with zanamivir when antiviral treat-
ment began on the day of fever onset, compared with a
median of 3 days (range 2–5 days) when either drug was
initiated the day after fever onset]. Most patients were dis-
charged shortly after antiviral administration and all recovered
without complication.
15 In the USA, data were collected on 272
patients with inﬂuenza-like illness who tested positive for the
pandemic virus and were admitted to hospital for at least
24 h.
16 In a multivariable analysis of outcomes, the only vari-
able that was signiﬁcantly associated with a positive outcome
was the receipt of antiviral drugs within 2 days of illness
onset.
16 Between 29 May 2009 and 28 July 2009, the Hospital
for Tropical Diseases in Ho Chi Minh City, Vietnam also collected
data on antiviral efﬁcacy in 292 hospitalized patients (average
age: 26.4 years; range: 1–69 years) who tested positive for
the pandemic (H1N1) 2009 virus by RT–PCR.
17 All patients
received the standard treatment dose of oseltamivir (75 mg
twice daily) until RT–PCR negative. By day 3 of treatment,
62% of patients were RT–PCR negative, and by day 5, 86%
were negative (Figure 2).
17 After 24 h, 228/292 patients (78%)
were afebrile and all patients had a mild illness course. Two
patients remained RT–PCR positive for an extended period of
time (one up to day 8 and one up to day 14) despite oseltamivir
treatment, but no specimens collected after day 5 cultured
positive for the virus.
17
Of over 19000 pandemic H1N1 viruses that had been evalu-
ated by laboratories in the Global Inﬂuenza Surveillance
Network for antiviral drug resistance up to 4 December 2009,
almost all were susceptible to both oseltamivir and zanamivir.
18
At this time, 96 cases of oseltamivir-resistant infections had
been reported by the WHO, all of which carried the H275Y
mutation located in the neuraminidase gene.
18 Many of these
cases were associated with post-exposure prophylaxis or long-
term oseltamivir treatment in immunocompromised patients.
The WHO has not changed its clinical treatment guidance,
19
and antiviral drugs remain a key component of the public
health response when used as recommended.
14,19
Roles and responsibilities of Roche during
inﬂuenza pandemics
In the interests of transparency, Roche issued a document in May
2008 setting out its role and responsibilities in a pandemic, and
how the company plans to work with other stakeholders during
pre-pandemic and pandemic stages.
20 This was developed in
consultation with the Internal Public Policy Advisory Council on
Pandemic Preparedness (PAC), a body that includes experts
from governments, medicine and academia.
One of Roche’s key roles is to ensure a sustainable supply of
oseltamivir. Although manufacturing capacity at the end of
2004 was sufﬁcient to produce 28 million treatment courses
annually, the company has since invested in the development of
a global manufacturing network, involving 19 external partner
companies that can produce 400 million treatment courses
annually if required. Roche has also appointed sub-licensees in
China and India, and has undertaken a knowledge transferagree-
ment with a company in Africa, allowing these companies to
supply generic forms of oseltamivir for local use and for use in
selected developing nations. These initiatives are described in
more detail in the next section. Before the current pandemic
was declared, global oseltamivir stockpiles were sufﬁcient to
treat ,5% of the world’s population, so the initial demand from
health authorities responding to the new pandemic is expected
to exceed production capacity. To address this challenge, Roche
has been allocating supplies of oseltamivir according to protocols
consistent with the WHO publication, ‘Ethical Considerations in
Developing a Public Health Response to Pandemic Inﬂuenza’,
21
which states that ‘resources should be used to provide the
maximum possible health beneﬁt’. The principles of the policy
are to support pandemic response efforts of both the WHO
and national governments, while balancing the needs of Roche’s
shareholders and employees and society as a whole, and main-
taining a dialogue with the WHO and other international agencies
regarding antiviral allocation needs.
20 These principles will apply
to the extent permitted under local emergency legislation affect-
ing the company’s manufacturing and supply capabilities.
During the early stages of the current pandemic, orders for
oseltamivir from the WHO and governments were given priority
over new corporate orders and normal retail sales. Now that
Phase 6 has been reached, Roche will continue dialogue with
international agencies so that the objective of providing
maximum possible health beneﬁt in the allocation of oseltamivir
is still achieved. Where priorities for allocation cannot be agreed
on, Roche will allocate oseltamivir supplies for government
orders according to the ‘ﬁrst come, ﬁrst served’ principle,
whereby the date of the letter of intent or order will determine
the date of delivery of the ﬁrst consignment in a schedule of
deliveries.
Responding to the pandemic: current Roche
activities
Sustainable supply
Between 2004 and December 2009, Roche has fulﬁlled pan-
demic orders from governments worldwide, amounting to
350 million treatment courses of oseltamivir (3.5 billion doses).
When pandemic alert Phase 5 was announced in April 2009,
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Figure 2. Proportion of patients who were RT–PCR positive for pandemic
(H1N1) 2009 by the day following initiation of oseltamivir treatment
(n¼292). Figure derived from data in Hien et al.
17
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JACRoche immediately took steps to increase oseltamivir production
and, during May to September 2009, was able to produce
110 million treatment courses (1.1 billion capsules). After
September 2009, production output was accelerated, with the
goal of reaching a maximum of 33 million treatment courses
per month by early 2010, if this is required.
Support for developing countries
In 2005, Roche donated 3 million treatment courses of oseltami-
vir to the WHO for their exclusive use as a ‘rapid response stock-
pile’ to contain or slow the spread of infection at the site of a
pandemic outbreak. A ‘regional stockpile’ consisting of a further
2 million treatment courses was also donated to serve the
needs of developing countries. In May 2009, the rapid response
stockpile was deployed by the WHO for use in Mexico and 72
of the world’s lowest economy countries. In response, Roche
has made further donations to replenish these stockpiles and
to establish a ‘paediatric stockpile’ of 650000 courses of small
capsules for use by the WHO. Roche has also initiated the
Tamiﬂu Reserves Program (TRP) for the world’s lowest economy
countries. This provides those countries with an insurance
policy, by securing supply of oseltamivir for the management
of a novel inﬂuenza strain deﬁned by the WHO to have signiﬁcant
and current pandemic potential. Eligible countries will pay a sub-
stantially reduced price for oseltamivir stockpiles to be built and
shipped at the time of an inﬂuenza pandemic or when required
by the government. The countries covered by this are all 72
countries of GAVI (Global Alliance for Vaccines and Immuniz-
ations) except India, which has its own generic manufacturing
capability.
As mentioned previously, sub-licences have been granted to
Shanghai Pharmaceuticals and the HEC Group to produce a
generic version of Tamiﬂu for China, and to Hetero for supply
to India and some developing countries. Roche also signed a
knowledge transfer agreement with the South African manufac-
turer Aspen Pharmaceuticals to support them in supplying a
generic version of oseltamivir for African countries.
Increasing access to oseltamivir
Other activities Roche is pursuing will help governments and
other provider organizations to gain the maximum beneﬁt from
their oseltamivir stockpiles during the pandemic. The ﬁrst stock-
piles were started in 2004, and the 5 year shelf-life for some of
those stocks expired (technically) in 2009. As longer term stab-
ility data indicate that this stock is still viable, Roche has
applied for shelf-life extension from 5 to 7 years. The shelf-life
of stockpiled product has already been extended to 7 years in
the USA and some European countries.
Roche will shortly seek regulatory approval for reprocessing
expired capsules in government stockpiles to recover active
pharmaceutical ingredient (API), so that oseltamivir base can
be incorporated into new capsules and small capsules with a 5
or 7 year shelf-life and supplied at a lower cost than de novo
manufacture. Smaller oseltamivir capsules (30 and 45 mg)
have been developed by Roche speciﬁcally for use in younger
patients, and offer governments the opportunity to build stock-
piles that are appropriate for local demographics.
Clinical study programme
A number of clinical trials are under way that will generate
information on the treatment of pandemic inﬂuenza (H1N1)
2009 with oseltamivir (Table 2). Patients infected with the pan-
demic virus and other seasonal inﬂuenza viruses are being
recruited.
The standard treatment regimens for adults and children
are expected to be effective against the pandemic (H1N1)
2009 virus, but clinical evidence for this is still to be collected.
It is possible that increasing the dosage could help to control
viral shedding, particularly as anecdotal reports suggest this
is prolonged in patients with pandemic (H1N1) 2009 disease.
New studies have been initiated to evaluate the virological efﬁ-
cacy of doubling the dose (from 75 to 150 mg twice daily) or
the duration (from 5 to 10 days), or both of these; these
studies also monitor emergence of resistance. Further trials
speciﬁcally assess the emergence and transmissibility of drug-
selected resistant variants with the standard treatment
regimen. One of these, the Inﬂuenza Resistance Information
Study (IRIS; NV20237), aims to recruit 1200 patients per year
(adults and children aged  1 year) from northern and southern
hemisphere countries over three consecutive inﬂuenza seasons,
ﬁnishing in 2011. The study does not have a ﬁxed treatment
regimen—physicians choose the most appropriate therapy for
each patient, allowing comparison of a variety of treatments
in patients infected with resistant and susceptible virus
strains. Two smaller observational studies in the UK and
South Africa look speciﬁcally at the incidence of drug resistance
in patients treated with a standard course of oseltamivir. In
the UK study, both the emergence of resistance and the trans-
mission of resistant strains to household members are being
measured.
The effectiveness of oseltamivir in treating pandemic
(H1N1) 2009 in some patient sub-populations known to be
at higher risk of severe disease, such as young children and
those with co-existing illnesses, has yet to be established.
This is being addressed through a series of four studies; the
ﬁrst of these, which started in 2007, is comparing a standard-
dose with a high-dose regimen in 250 immunocompromised
solid organ or stem cell transplant recipients. A second study
is examining the pharmacokinetics and safety of oseltamivir
in young infants with pandemic (H1N1) 2009; this open-label
study uses an investigational treatment regimen (2–3 mg/kg
twice daily for 5 days) in 100 inﬂuenza-infected infants, strati-
ﬁed into those aged 3–,12 months and those aged
,3 months. Two studies are being performed in intensive
care unit (ICU) patients infected with inﬂuenza in Canada to
evaluate administration of oseltamivir by nasogastric tube. A
smaller initial study is assessing pharmacokinetics and safety,
and will be followed by a nationwide multicentre study in
240 critically ill inﬂuenza patients that will also assess efﬁ-
cacy and the incidence of resistance with standard and high
doses of oseltamivir. Pharmacokinetics will also be assessed
in pregnant women.
Two further studies are also assessing the pharmacokinetics
of oseltamivir; the ﬁrst is investigating the utility of oseltamivir
and rimantadine as a combination therapy in healthy volunteers
and the second is investigating whether the pharmacokinetic
proﬁle of oseltamivir is the same in obese individuals as in non-
Reddy
ii38obese individuals. Evidence from the Americas suggests that
obese patients could be at higher risk of complications if infected
with pandemic (H1N1) 2009 inﬂuenza.
4 Two further studies in
France are assessing the efﬁcacy, safety and incidence of resist-
ance of combinations of oseltamivir with amantadine or zanami-
vir compared with monotherapy.
Finally, Roche is working with various groups to measure the
real-life utilization of Tamiﬂu during the pandemic, by analysing
patient registries that will collect information from speciﬁed vul-
nerable populations infected with pandemic (H1N1) 2009 virus.
By doing this, a better understanding will be gained of the clinical
course of the disease and the safety of oseltamivir treatment in
these populations. In addition, Roche will adapt its existing phar-
macovigilance process to collect data on the use of Tamiﬂu in a
pandemic situation.
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Table 2. Clinical trials investigating the treatment of pandemic (H1N1) 2009 with oseltamivir
Clinicaltrials.gov/Roche
registration number
a Patient group Treatment regimen Outcomes to be assessed
NCT00949533 infected patients  5 years (Brazil)
(n¼125)
75 or 150 mg of oseltamivir twice daily for
5d a y s
clinical outcomes,
virological assessment
NV22155 infected patients  1 year (USA) (n¼400) 75 or 150 mg of oseltamivir twice daily for
5o r1 0d a y s
clinical outcomes,
virological assessment
NV20237 infected patients  1 year (northern and
southern hemispheres) (n¼1200 per
year)
determined by treating physician clinical outcomes,
resistance
MV22841 infected patients  1 year (South Africa)
(n¼125)
75 mg of oseltamivir twice daily for 5 days clinical outcomes,
virological assessment
ML22879 infected patients  1 year (UK) (n¼100) 75 mg of oseltamivir twice daily for 5 days clinical outcomes,
virological assessment
NCT00545532 immunocompromised transplant patients
 1 year (USA and Europe) (n¼250)
75 or 150 mg of oseltamivir twice daily for
10 days
efﬁcacy and safety,
resistance
NCT00988325 infected infants ,1 year (Europe)
(n¼100)
2–3 mg/kg oseltamivir twice daily for 5 days clinical outcomes,
pharmacokinetics, safety
NCT01010087 infected patients with critical illness
(Canada) (n¼240)
75 or 225 mg of oseltamivir twice daily for
10 days
pharmacokinetics, safety
NCT00844155 infected patients with respiratory failure
(Canada) (n¼60)
75 mg or 150 mg of oseltamivir, single dose pharmacokinetics, efﬁcacy
and safety, resistance
NP22770 healthy non-infected adult volunteers
(n¼40)
75 mg of oseltamivir or 100 mg of
rimantadine twice daily for 5 days alone
and in combination
pharmacokinetics, safety
NCT01002729 obese non-infected adult volunteers
(Canada) (n¼20)
75 mg of oseltamivir twice daily for 7 days pharmacokinetics, safety
NCT00873886 pregnant female volunteers (USA) (n¼39) 75 mg of oseltamivir, single dose pharmacokinetics, safety
NCT00830323 infected adults 18–65 years (France)
(n¼60)
75 mg of oseltamivir either alone or combined
with 100 mg of amantadine or 5 mg of
zanamivir twice daily for 5 days
clinical outcomes,
virological assessment
NCT00799760 infected adults 18–65 years (France)
(n¼900)
75 mg of oseltamivir or 10 mg of zanamivir or
both combined twice daily for 5 days
clinical outcomes,
virological assessment
NV25182 children ,2 years (Europe) (n 900) determined by physician safety
Not applicable (registry) infected pregnant women (Europe and
Japan)
determined by treating physician pregnancy outcome
aClinicaltrials.gov registration number (commencing NCT) supplied if known; otherwise, Roche internal clinical trial code provided.
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